郎慧珠-教授

郎慧珠

研究室
聯絡電話
傳真電話
電子郵件

教授

護理館5樓521室
(02)2826-7015
(02)2823-7298
hclang@nycu.edu.tw

研究領域

成本效益評估
醫院績效管理

開授課程

健康科技與經濟評估
醫院作業管理
醫療決策分析

學歷
美國約翰霍普金斯大學醫療管理博士
國立陽明大學公共衛生碩士
中國醫藥大學公共衛生學士

經歷
國立陽明大學醫務管理研究所副教授
國立陽明大學醫務管理研究所助理教授
國立陽明大學醫務管理研究所講師

期刊論文
Lin WY1, Tan EC 2, Cheng E, Lang HC*. Real-World Cost-Effectiveness of Post-Acute Care or General Rehabilitation Care. MOST 105-2410-H-010 -012 -SS2.
Tzeng YH, Yin WH, Lin KC, Wei J, Liou HR, Sung HJ, Lang HC. Factors Associated With the Utilization of Outpatient Virtual Clinics: Retrospective Observational Study Using Multilevel Analysis. J Med Internet Res. 2022 Jul 31. doi: 10.2196/40288. Epub ahead of print. PMID: 35917486.
Chiu CM, Lin CS, Chen MS, Lang HC*. Evaluating the Comparative Efficiency of Medical Centers in Taiwan: A Dynamic Data Envelopment Analysis Application. BMC Health Services Research. 2022; Apr 2;22(1):435. 台灣19家醫學中心之財務結構與營運效能分析 PI-亞東醫院產學合作
Chiou LJ, Lang HC*. Potentially Preventable Hospital Readmissions after Patients’ First Stroke in Taiwan. Submitted to Scientific Report. MOST 105-2410-H-010 -012 -SS2. Science Report 2022; Mar 8;12(1);3743. doi: 10.1038/s41598-022-07791-3.
Leung JH, Chang CW, Chan AL, Lang HC*. Cost-effectiveness of immune checkpoint inhibitors in the treatment of non-small-cell lung cancer as a second line in Taiwan. Future Oncol. 2022 Feb 2. doi: 10.2217/fon-2021-0785. Online ahead of print. 醫藥品查驗中心
Lin CS, Chiu CM, Huang YC, Lang HC, Chen MS. Evaluating the Operational Efficiency and Quality of Tertiary Hospitals in Taiwan: The Application of the EBITDA Indicator to the DEA Method and TOBIT Regression. Healthcare (Basel). 2021 Dec 29;10(1):58. doi: 10.3390/healthcare10010058. 台灣19家醫學中心之財務結構與營運效能分析 PI-亞東醫院產學合作
郎慧珠. COVID-19疫情對於醫療產業及民眾健康之衝擊及反思. 人文與社會科學簡訊. 科技部人文及社會科學研究發展司.2021; 22(4): 31-37.
Leung JH, Lang HC, Wang SY, Lo HF, Chan AL. Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer. Expert Rev Pharmacoecon Outcomes Res. 2022 Apr; 22(3): 489-496. doi: 10.1080/14737167.2021.1954506. 全民健康保險納入癌症新藥之衝擊 PI MOST 107-2410-H-010-011
Leung WC, Lang HC, Wang SY, Leung H, Chan LF. Cost‐utility analysis of stereotactic body radiotherapy plus cetuximab in previously irradiated recurrent squamous cell carcinoma of the head and neck. Expert Review of Pharmacoeconomics & Outcomes Research. 2021Jun;21(3):489-495. doi: 10.1080/14737167.2021.1890585. Epub 2021 Mar 17. 全民健康保險納入癌症新藥之衝擊 PI MOST 107-2410-H-010-011
Yang CP, Li CY, Huang WJ, Yu HL, Yang CC, Lu MC, Lang HC, Yan YH. Short-, mid- and long-term associations between PM2.5 and stroke incidence in Taiwan. J Occup Environ Med 2021 Sep 1;63(9):742-751.採用健保資料庫進行風險校正之成本效益分析:以腦中風治療為例 MOST 105-2410-H-010 -012 -SS2
Chen TT, Hsueh YS, Chen YH, Lang HC, Fan CM, Wei CJ, Wang TL. The validity of acute myocardial infarction process-based measures on public report card: are they varied by patient outcomes at patient- and hospital- levels. Taiwan J Public Health 2019;38(3):289-300. MOST 105-2410-H-010 -012 -SS2
Yang CP, Cheng HM, LuMC, Lang HC*. Association between continuity of care and survival in Taiwanese stroke patients: a 9-year cohort study. PLos One. 2019 May 22; 14(5):ee0216495. doi: 10.1371/journal.pone. 0216495. eCollection 2019. MOST 105-2410-H-010 -012 -SS2
Cheng HM, Chiou LJ, Chen TC, Sung SH, Chen CH, Lang HC*. Real-world cost-effectiveness of drug-eluting stents vs. bare-metal stents for coronary heart disease-A five-year follow-up study. Health Policy. 2019 Feb;123(2):229-234. doi: 10.1016/j.healthpol.2018.11.010. Epub 2018 Nov 28. NSC 101-2410-H-010
Hsu CS, Lang HC, Huang KY, Chao YC, Chen CL. Risks of hepatocellular carcinoma and cirrhosis-associated complications in patients with rheumatoid arthritis: a 10-year population-based cohort study in Taiwan. Hepatol Int. 2018 Nov;12(6):531-543. doi: 10.1007/s12072-018-9905-7. Epub 2018 Nov 14. PMID: 30426396.
蔣靜怡,郎慧珠.台灣診所之歇業與存活研究及其相關因素探討─以2000年至2010年新設西醫診所研究為例.台灣衛誌 2017年12月的第36卷第6期.
Chang FM, Wang YP, Lang HC, Tsai CF, Hou MC, Lee FY, Lu CL. Statins decrease the risk of decompensation in HBV- and HCV-related cirrhosis: a population-based study. Hepatology. 2017 Sep;66(3):896-907. doi: 10.1002/hep.29172. Epub 2017 May 8. NSC 101-2410-H-010
Sung SH, Chen TC, Cheng HM, Lee JC, Lang HC, Chen CH. Comparison of Clinical Outcomes in Patients Undergoing Coronary Intervention with Drug-Eluting Stents or Bare-Metal Stents: A Nationwide Population Study. Acta Cardiol Sin. 2017 Jan;33(1):10-19.
Chiu YM, Chuang MT, Lang HC. Medical costs incurred by organ damage caused by active disease, comorbidities and side effect of treatments in systemic lupus erythematosus patients: a Taiwan nationwide population-based study. Rheumatol Int. 2016 Nov;36(11):1507-1514. Epub 2016 Aug 17.
Lang HC, Chen HW, Chiou TJ, Chan AL. The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan. J Med Econ. 2016 Oct; 19(10); 923-7.
Hsu CS, Lang HC, Huang KY, Lin HH, and Chen CL. Association of Rheumatoid Arthritis and Hepatitis B infection: a Nationwide Nested Case-Control Study from 1999 to 2009 in Taiwan. Medicine(Baltimore). 2016 May;95(18):e3551.
Lang HC, Lee HC, Lee SS, Lin HY,Chiu YM,. The impact of introducing biologics to patients with rheumatoid arthritis in Taiwan: A population based trend study. International Journal of Rheumatic Diseases. Int J Rheum Dis.. 2016 Nov. 19(11): 1112-1118.doi: 10.1111/1756-185X.12813. Epub 2016 Feb 18.
Chen SF, Wang IJ, Lang HC*. Risk of major depression in patients with chronic renal failure on different treatment modalities: A matched-cohort and population-based study in Taiwan. Hemodial Int. 2016 Jan;20(1):98-105. doi: 10.1111/hdi.12334. Epub 2015 Jul 14.
Cheng JS, Tsai WC, Lin CL, Chen L, Lang HC, Hsieh HM, Shin SJ, Chen T, Huang CT, Hsu CC. Trend and factors associated with healthcare use and costs in type 2 diabetes mellitus: A decade experience of a universal health insurance program. Med Care. 2015 Feb;53(2):116-24.
Chiu YM, Lang HC*, Lin HY, Yang MT, Fang CH, Yan YW, Schabert VF, Tang B. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan. Int J Rheum Dis. 2014 Dec;17 Suppl 3:9-19.
Chiu YM, Lai MS, Lin HY,Lang HC, Lee LJ, Wang JD. Disease activity affects all domains of quality of life in patients with rheumatoid arthritis and is modified by disease duration. Clin Exp Rheumatol. 2014 Nov-Dec;32(6):898-903
Grøn KL, Ørnbjerg LM, Hetland ML, Aslam F, Khan N, Jacobs JWG, Henrohn D, Rasker H, Kauppi M, Lang HC, et al. The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis: results from 34 countries participating in the Quest-RA programme. Clin Exp Rheumatol. 2014 Nov-Dec;32(6):869-77 NSC 99-2410-H-010 -001
Chen HY, Chang HR, Lang HC*. Effects of Generic Drug substitution on Diabetes Therapy. Patient Prefer Adherence. 2014 Jan 29;8:127-33.
Shih CL,Chen CH, Sheu CF, Lang HC*, Hsieh CL. Validating and improving the reliability of the EORTC QLQ-C30 using a multidimensional Rasch model. Value Health. 2013 Jul-Aug;16(5):848-54.
Lang HC, Chang K, Ying YH*. Quality of Life, Treatment, and Patient Willingness to Pay for a Cure for Cervical Cancer in Taiwan. Health Econ. 2012 Oct;21(10):1217-33. (SCI). (Impact factor: 1.946;Rank: 12.13%)
Lang HC*, Wu SL. Lifetime Costs of the Top Five Cancers in Taiwan. Eur J Health Econ. 2012 Jun;13(3):347-53. (SCI). (Impact factor: 1.755;Rank: 15.41%)
Lang HC*. Willingness to Pay for Lung Cancer Treatment. Value in Health 2010; 13(6):743-9. ). (SCI). (Impact factor: 2.342;Rank: 8.85%)
Lang HC*, Scheffler RM, Hu TW. The Discrepancy in Attention Deficit Hyperactivity Disorder (ADHD) Medications Diffusion: 1994-2003-A global pharmaceutical data analysis. Health Policy 2010;97:71-78. (SCI).(Impact factor: 1.383;Rank: 51.72%)
Lu CL, Lang HC, Luo JC, Liu CC, Lin HC, Chang FY, Lee SD. Increasing Trend of the Incidence of Esophageal Squamous Cell Carcinoma, but not Adenocarcinoma, in Taiwan. Cancer Causes and Control. 2010;21(2):269-74.(SCI). (Impact factor: 2.789;Rank: 22.54%)
Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae, SC Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010;19(4):422-37.(SCI). (Impact factor: 1.946;Rank: 12.13%)
Lang HC*, Chung L, Shun SC, Hsieh CL, Lan CF. Validation of EQ-5D in patients with cervical cancer in Taiwan. Supportive Care in Cancer 2010; 21(2): 269-74.(SCI). (Impact factor: 2.058;Rank: 25.00%)
Lang HC*, Li MS. Willingness to Pay to Sustain and Expand National Health Insurance Services in Taiwan. BMC Health Service Research 2008;8:261
Lang HC*, Wu JC, Yen SH, Lan CF, Wu SL. The lifetime Cost of Hepatocellular Carcinoma. Applied Health Economics and Health Policy.Appl Health Econ Health Policy 2008; 6 (1): 55-65.
Pu CY, Lan VM, Lan CF, Lang HC. The determinants of traditional Chinese medicine and acupuncture utilization for cancer patients with simultaneous conventional treatment. Eur J Cancer Care. 2008 ;17(4):340-9.
Lu CL, Lang HC, Chang FY, Chen CY, Luo JC,Lee SD. Social and medical impact, sleep quality and pharmaceutical costs of heartburn in Taiwan. Aliment Pharmacol Ther 2005;22: 739-47.
Lu CL, Chang FY, Lang HC, Chen CY, Luo JC,Lee SD. Gender Difference on the Symptoms, health seeking behavior, social impact and sleep quality in Irritable Bowel Syndrome: A Rome II-based survey in an apparent healthy adult Chinese population in Taiwan. Aliment Pharmacol Ther 2005;21: 1497-505.
Liu CM, Chien CW, Chou P, Liu JH, Chen VT, Wei J, Kuo YY, Lang HC. An Analysis of Job Satisfaction Among Physician Assistants in Taiwan. Health Policy. 2005; 73(1); 66-77.
Lu CL, Lang HC, Chang FY, Chen CY,Luo JC,Wang SS,Lee SD. Prevalence and Health/Social Impacts of Functional Dyspepsia in Taiwan: a Study Based on Rome Criteria Questionnaire Survey Assisted with Endoscopic Exclusion among a Physical Checkup Population. Scand J Gastroenterology. 2005; 40 (4): 402-411.
Lang HC*. Economic Grand Rounds: Patients' and Caregivers' Willingness to Pay for a Cure for Schizophrenia in Taiwan. Psychiatr Serv. 2005 Feb; 56(2): 149-51.
Lang HC*, Su TP. The Cost of Schizophrenia Treatment in Taiwan. Psychiatric Services. 2004; 55(8): 928-930.
Lang HC*, Lai MS, Chen GT. Expenditures and Prescription Policies for Diseases with High Utilization of the National Health Insurance. Journal of Formosan Medical Association 2004;103:180-5.
Lang HC*, Chi CH, Liu CM. Impact of Case Payment Reimbursement Method on the utilization and Costs of Laparoscopic Cholecystectomy. Health Policy. 2004;67:195-206.
Lu CL,Chen CY,Lang HC,Wang SS,Chang FY,Lee SD. Current Patterns of Irritable Bowel Syndrome Presenting in a Chinese Population of Taiwan: Based on the Rome II Questionnaire. Aliment Pharmacol Ther. 2003; 18: 1159-69.
Lee ML, Chen CJ, SU IJ, Chen KT, Yeh CC, King CC, Wu YC, Ho MS, Jiang DD, Lin WF, Lang HC, Lin T, Wang JT, Chen CH, SARS Prevention Task Force, Execute Yuan, Taiwan, R.O.C. WHO, Department of Communicable Disease Surveillance and Response, Taiwan SARS Investigative Team, CDC. Use of Quarantine to Prevent Transmission of Severe Acute Respiratory Syndrome—Taiwan, 2003. MMWR 2003; 680-683.
Lang HC*, Lee C. The Transition of Taiwan Provicial Hospital- A Survey of High Ranking Officials. Chin J Public Health. [Chinese] 2001;20(1); 15-26.
Lang HC*, Lan CF. Contingent Valuation Method- A Method to Elicit Willingness to Pay. Public Health Quarterly. [Chinese] 2001;27(4) 261~276.
Bishai D, Lang HC. The Willingness to Pay for Wait Reduction: The Disutility of Queues for Cataract Surgery in Canada, Denmark and Spain. J. Health Econ. 2000;19:219-230.
Chung FL, Cheng HC &Lang HC. Willingness to Share Costs of Health Insurance. J Formosan Med Assoc. 1992;91:s99-108.

研討會論文
Chiu CM, Huang Y, Chen MS, Lin CS, Lang HC*. The Efficiency Analysis of 19 Medical Centers in Taiwan, was accepted to ISPOR Asia Pacific 2020. ISPOR Asia Pacific 2020. Virtual conference
Lang HC, Tan ECH, Lin WY, Chang CW. Real-World Cost and Effectiveness Analysis Of Post-Acute Care Vs. Non-Pac for Stroke Patients after Discharge from Hospital. ISPOR 2019 Europe 2-6 November 2019, Copenhagen, Denmark.
Chang CW (張智雯). Cost-effectiveness of the Second Line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC). ISPOR 2019. 18-22 May 2019. New Orleans, LA, USA.
4. Kuo WJ(郭琬蓉), Lang HC, Lin CL. Budget Impact Analysis of Novel Direct-Acting Antivirals for Chronic Hepatitis C Virus Infection in Taiwan. ISPOR 2019. 18-22 May 2019. New Orleans, LA, USA.
Lang HC, Tan ECH, Yang CK, Chang CW, Yang MH. Cost-effectiveness of immunotherapy strategies for advanced melanoma in Taiwan. ISPOR Asia Pacific 2018. 8-11 September 2018, Tokyo, Japan.
Lang HC, Lin WC, Niu DM. Economic Evaluation of Neonatal Screening for Congenital Hypothyroidism. ISPOR 20th Annual European Congress4-8 November 2017, Glasgow, Scotland
Lin YL, Lang HC*. Cost-Effectiveness Analysis of Laparoscopic Surgery for Presumed Leiomyomas.ISPOR 19th Annual European Congress. 29 Oct.-2 Nov. 2016, Vienna, Austria
Chen RCY, Lang HC, Chuang SY, Cheng HM. Application Of Risk Adjusted Cost-Effectiveness Analyses For Stroke Treatment. ISPOR 19th Annual European Congress. 29 Oct.-2 Nov. 2016, Vienna, Austria
Lang HC, Cheng E. The Relationship between Economic Business Cycle and Health Care Utilization. iHEA Italy, Milan July 13-15, 2015
Wang YP, Lang HC, Lu CL. Use of ursodeoxycholic acid and the risk of colorectal cancer: a nationwide, population based, case-control database study
Lang HC1, Chen TC(陳姿菁)1, Chen CH(陳震寰). The Cost Comparison of Drug-Eluting Stents (DES) and Bare-mental Stents (BMS) – A Retrospective Cohort Matched Study. ISPOR 17th Annual European Congress. 8-12 November 2014, Amsterdam, The Netherlands
Chang JY (張仁洋), Lang HC. The Economic Cost of Rheumatoid Arthritis in Taiwan.Asia-Pacific Conference. 6-9 September 2014. Beijing.
Chen SF(陳世豐), Wang IJ, Lang HC. A Comparison of Major Depression Incidence among Patients with Chronic Kidney Disease and End Stage Renal Disease of Different Renal Replacement Therapy Modalities. Taiwan Society of Nephrology annual Meeting, 2013
Lang HC, Chen HF(陳慧芬), Lin HY. The medication costs of pheumatoid arthritis- comparing before and after introduction of the biologics. 9th iHEA Sydney, Australia, 10 June, 2013.
Lang HC, Lee HC, Lin HY. The medication costs of Rheumatoid Arthritis- comparing before and after introduction of the biologics. ISPOR 5th Asia-Pacific Conference. 2-4 September, 2012.Taipei, Taiwan.
Chen HF(陳慧芬), Lang HC. Cost-effectiveness of Biological Treatments in Patients with Rheumatoid Arthritis in Taiwan. ISPOR 5th Asia-Pacific Conference. 2-4 September, 2012.Taipei, Taiwan.
Lang HC, Tan CH. The effect of price containment on the trend of pharmaceutical expenditure from 1999 to 2007 in Taiwan. ISOPR 4rd Asia-Pacific Conference5-7 September, 2010.Phuket, Thailand
Chang HR(張慧如), Chen HY(陳慧櫻), Lang HC. The Effect of Metformin Brand Shift by Hospital on Diabetic Treatment Outcomes. ISOPR 4rd Asia-Pacific Conference5-7 September, 2010.Phuket, Thailand.
Chen HY(陳慧櫻), Chang HR(張慧如), Lang HC. The Effect of Metformin Brand Shift by Hospital on Antidiabetics Utilization. ISOPR 4rd Asia-Pacific Conference5-7 September, 2010.Phuket, Thailand.
Lin YS, Lang HC, Chen SC, Lee JL. The Effect of the "National Health Insurance Family Doctors Integrated Care" program on Patients' Health Care Utilization. 41th APACPH. 3-6 December, 2009 Taipei, Taiwan.
Huang PP, Lang HC. Reconciliation of medication discrepancies of admitted patients in a general teaching hospital in Taiwan. The 4th Asian Conference on Pharmacoepidemiology. Oct.23-25,2009.
Tsutani K, Takeru S, Lang H. Willingness to pay for a QALY in East Asia. ISOPR 3rd Asia-Pacific Conference. Korea, September 7-9, 2008
Lang HC, Lan CF. Patient’s willingness to pay for a new drug treatment of lung cancer. ISOPR 3rd Asia-Pacific Conference. Korea, September 7-9, 2008
Lang HC, Lan CF. The lifetime cost cervical cancer in Taiwan. ISPOR 13th Annual International Meeting. , Ontario, Canada May 3-7, 2008.
Lang HC. ADHD medications in the US and OECD countries: Determinants of quantity and price. AcademyHealth. June 25-27, 2006. Seattle, U.S.A.
Lang HC. Incremental lifetime cost of liver cancer-Incidence-based approach. ISPOR 2nd Asia-Pacific Conference. March 5-7, 2006. Shanghai, China.
Lang HC, Huang LH. Incremental Lifetime Cost in Five Leading Cancers in Taiwan-Incidence Base Approach. 4th iHEA. July 10, 2005. Barcelona, Spain.
Lang HC. Patients’ Willingness to Pay for NHI. International Conference on Pharmaceutical Innovation. May 26-27. 2005. Taipei, R.O.C.
Scheffler R, Lang HC. Economic Analysis of the Global Market for ADHD Medications. May 26-27, 2005. Taipei, R.O.C.
Lang HC. Health-Related Quality of Life of Patients with Cervical Cancer in Taiwan. International Society for Quality of Life Research (ISOQOL) 2004 Symposium. June 27-29. Boston, U.S.A.
Chi CH, Lang HC. Methodological Issues In Willingness to Pay Tax. 1st Asia-Pacific ISPORT. September 2, 2003. Kobe, Japan.
Lang HC. Cost of Schizophrenia – An Application of Closed-ended Willingness to Pay Study. “24th Annual Meeting of the Society for Medical Decision Making”. October 22, 2002. Baltimore, U.S.A.
Lang HC. The Austria Pharmaceutical Benefit Advisory Guideline and Pharmacoeconomics. NHI “Technology Assessment” May, 2001. Taipei